Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression

Journal of Vascular Research

Volumn 49, Issue 3, 2012, Pages 260-266

  Ashoff, Astrid ^a   Qadri, Fatimunnisa ^c   Eggers, Reinhard ^b   Jöhren, Olaf ^a   Raasch, Walter ^a   Dendorfer, Andreas ^a,d  

^a Institutes of A Experimental and Clinical Pharmacology and Toxicology   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Capillaries; Diabetic angiopathies; Oxygen radicals; Peroxisome proliferator activated receptor ; Rarefaction; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; GLUCOSE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 3ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; STREPTOZOCIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CAPILLARY DENSITY; CAPILLARY RAREFACTION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEART; HEART MUSCLE CELL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; MICROANGIOPATHY; MICROCIRCULATION; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE; SKIN CAPILLARY; STREPTOZOCIN DIABETES; VASCULARIZATION; WISTAR RAT;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CAPILLARIES; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; MALE; PPAR GAMMA; RATS; RATS, WISTAR; STREPTOZOCIN; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858989832     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000335214     Document Type: Article

References (37)

1. Levy BI, Schiffrin EL, Mourad JJ, Agostini D, Vicaut E, Safar ME, Struijker-Boudier HA: Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. Circulation 2008; 118: 968-976.
2. Frisbee JC: Hypertension-independent microvascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Microcirculation 2005; 12: 383-392. (Pubitemid 41122463)
3. Prewitt RL, Chen II, Dowell R: Development of microvascular rarefaction in the spontaneously hypertensive rat. Am J Physiol 1982; 243:H243-H251. (Pubitemid 12051559)
4. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GC: Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99: 1873-1879. (Pubitemid 27175934)
5. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Järvinen H, Christin L, Secomb TW, Bogardus C: Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80: 415-424.
6. Frisbee JC, Samora JB, Peterson J, Bryner R: Exercise training blunts microvascular rarefaction in the metabolic syndrome. Am J Physiol Heart Circ Physiol 2006; 291:H2483-H2492.
7. Goodwill AG, Frisbee SJ, Stapleton PA, James ME, Frisbee JC: Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. Microcirculation 2009; 16: 667-684.
8. Battegay EJ, de Miguel LS, Petrimpol M, Humar R: Effects of anti-hypertensive drugs on vessel rarefaction. Curr Opin Pharmacol 2007; 7: 151-157. (Pubitemid 46404741)
9. Duan SZ, Usher MG, Mortensen RM: Peroxisome proliferator-activated receptorgamma-mediated effects in the vasculature. Circ Res 2008; 102: 283-294. (Pubitemid 351271648)
10. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H: Thiazolidinedione ameliorates renal injury in experimental diabetic rats through antiinflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007; 292:F1141-F1150. (Pubitemid 46578056)
11. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM: Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol 2005; 25: 1810-1816. (Pubitemid 41243447)
12. Frisbee JC: Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2005; 289:R307-R316. (Pubitemid 41060480)
13. Dendorfer A, Dominiak P, Tempel K, Raasch W: Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for longterm antihypertensive efficacy? J Hypertens 2005; 23: 1861-1867. (Pubitemid 43000314)
14. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36: 169-180.
15. Heidbreder M, Fröhlich F, Jöhren O, Dendorfer A, Qadri F, Dominiak P: Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J 2003; 17: 1541-1543.
16. Vogt CJ, Schmid-Schönbein GW: Microvascular endothelial cell death and rarefaction in the glucocorticoid-induced hypertensive rat. Microcirculation 2001; 8: 129-139. (Pubitemid 33600465)
17. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA: PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke 2010; 41: 1266-1270.
18. Han B, Baliga R, Huang H, Giannone PJ, Bauer JA: Decreased cardiac expression of vascular endothelial growth factor and redox imbalance in murine diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2009; 297:H829-H835.
19. Emanueli C, Salis MB, Pinna A, Stacca T, Milia AF, Spano A, Chao J, Chao L, Sciola L, Madeddu P: Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 2002; 106: 993-999. (Pubitemid 34925336)
20. Kobayashi N, DeLano FA, Schmid-Schönbein GW: Oxidative stress promotes endothelial cell apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 2005; 25: 2114-2121. (Pubitemid 41416309)
21. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M: Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 2002; 51: 2241-2248. (Pubitemid 34729031)
22. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, Aiello LP, Kern TS, King GL: Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009; 15: 1298-1306.
23. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790. (Pubitemid 30212409)
24. Biscetti F, Straface G, Arena V, Stigliano E, Pecorini G, Rizzo P, De Angelis G, Iuliano L, Ghirlanda G, Flex A: Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARgamma stimulation. Cardiovasc Diabetol 2009; 8: 49.
25. Gealekman O, Burkart A, Chouinard M, Nicoloro SM, Straubhaar J, Corvera S: Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production. Am J Physiol Endocrinol Metab 2008; 295:E1056-E1064.
26. Redondo S, Ruiz E, Santos-Gallego CG, Padilla E, Tejerina T: Pioglitazone induces vascular smooth muscle cell apoptosis through a peroxisome proliferator-activated receptor-gamma, transforming growth factor-beta1, and a Smad2-dependent mechanism. Diabetes 2005; 54: 811-817. (Pubitemid 40322086)
27. Billiet L, Furman C, Larigauderie G, Copin C, Page S, Fruchart JC, Brand K, Rouis M: Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. J Cell Physiol 2008; 214: 183-191. (Pubitemid 350220073)
28. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, Eichinger F, Gaiser S, Schmid H, Rastaldi MP, Schrier RW, Schlöndorff D, Cohen CD: Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007; 18: 1765-1776. (Pubitemid 46870313)
29. Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, Galiano RD, Du XL, Grogan R, Galvez MG, Januszyk M, Brownlee M, Gurtner GC: The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA 2009; 106: 13505-13510.
30. Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y: Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 2001; 50: 1166-1170. (Pubitemid 32374549)
31. Chintalgattu V, Harris GS, Akula SM, Katwa LC: PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res 2007; 74: 140-150. (Pubitemid 46366953)
32. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008; 451: 1008-1012. (Pubitemid 351301733)
33. Zolk O, Solbach TF, Eschenhagen T, Weidemann A, Fromm MF: Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure. Biochem Biophys Res Commun 2008; 376: 315-320.
34. Blasi ER, Heyen J, Hemkens M, McHarg A, Ecelbarger CM, Tiwari S: Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy Sprague-Dawley rats. PPAR Res 2009; 2009: 237865.
35. Yue Tl TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptorgamma agonist rosiglitazone. Circulation 2001; 104: 2588-2594. (Pubitemid 33104798)
36. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ: Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117: 2791-2801. (Pubitemid 47529610)
37. Baraka A, AbdelGawad H: Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol Ther 2010; 15: 175-181.